Condition: Febrile Neutropenia · Sponsor: Instituto de Investigación Biomédica de Salamanca
Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management. This study aims to characterize the human and microbial plasma proteome using high-resolution mass spectrometry to identify biomarker combinations ("combitypes") capable of predicting complications in oncohematologic patients with FN. A cohort of 350 adult patients with high-risk FN and initially uncomplicated clinical presentation will be enrolled across three tertiary hospitals. Plasma samples will be collected at fever onset (before antibiotic initiation) and after 48 hours. Proteomic data will be integrated with clinical information using multivariate and machine learning models to develop a predictive model for complications.
This description comes directly from the study's public registry record.
Jesús Francisco Bermejo Martín, MD PhD · +34923 29 45 41 · jfbermejo@usal.es
Nadia García Mateo, PhD · +34923 29 45 41 · nadiagarciamateo@ibsal.es
Always discuss trial participation with your own doctor first.
| Hospital Universitari Vall d'Hebron | Barcelona, Barcelona, Spain | Not Yet Recruiting |
| Complejo Asistencial Universitario de Salamanca | Salamanca, Salamanca, Spain | Recruiting |
| Hospital Universitario Virgen Macarena | Seville, Sevilla, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07277387